Acurx Announces Scientific Partnership with Leiden University Medical Center to Advance Development of Acurx's DNA Polymerase IIIC Inhibitor Antibiotics

Acurx entered a scientific partnership with Leiden University Medical Center to generate the first-ever 3D structure of DNA polymerase IIIC from MRSA, aiming to advance discovery of new antibiotics for this high-priority pathogen. The collaboration builds on prior research funded by Health-Holland and seeks to extend mechanistic understanding to enable systemic treatment of resistant Gram-positive infections. Acurx's lead candidate ibezapolstat is Phase 3 ready for C.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.